Technical Trend Improvement Spurs Upgrade
The primary catalyst for the upgrade was a notable change in the technical grade, which moved from bearish to mildly bearish. Weekly technical indicators have shown mild bullish signals, with the Moving Average Convergence Divergence (MACD) on a weekly basis turning mildly bullish, although the monthly MACD remains bearish. Similarly, the Know Sure Thing (KST) indicator is mildly bullish weekly but bearish monthly, indicating some short-term positive momentum despite longer-term caution.
Other technical measures present a mixed picture: the Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal, while Bollinger Bands remain mildly bearish on both timeframes. Daily moving averages continue to signal bearishness, and Dow Theory analysis shows no trend weekly but bearish monthly. The On-Balance Volume (OBV) indicator is mildly bullish weekly but neutral monthly, suggesting some accumulation in the short term.
These technical nuances have collectively improved the stock’s technical grade, justifying the upgrade from Strong Sell to Sell. The stock price has also reflected this shift, rising 2.30% on the day to ₹195.85, with intraday highs touching ₹198.50, though it remains well below its 52-week high of ₹457.25.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Valuation Grade Adjusted to Fair from Attractive
Alongside technical improvements, Tarsons Products’ valuation grade was downgraded from attractive to fair. The company currently trades at a price-to-earnings (PE) ratio of 49.05, which is high relative to many peers in the plastic products and healthcare services industries. Its price-to-book value stands at 1.66, while the enterprise value to EBITDA ratio is 11.66, indicating a moderate premium valuation.
Return on capital employed (ROCE) and return on equity (ROE) remain subdued at 3.93% and 3.28%, respectively, reflecting weak profitability. The enterprise value to capital employed ratio is 1.42, suggesting the stock is trading at a reasonable multiple relative to its capital base but not at a bargain level. Compared to peers such as Apollo Pipes, which is rated very expensive with a PE of 51.27, Tarsons Products’ valuation is fair but no longer attractive.
This shift in valuation grade reflects the market’s tempered expectations amid the company’s recent financial struggles and subdued profitability metrics.
Financial Trend Remains Negative Despite Some Stability
Financially, Tarsons Products continues to face headwinds. The company has reported negative results for three consecutive quarters, with the latest six-month profit after tax (PAT) at ₹9.27 crores, declining by 40.41%. Operating profit has contracted at an annualised rate of -18.84% over the past five years, signalling persistent challenges in growth.
Return on capital employed (ROCE) for the half-year period is low at 6.69%, and the debt-to-equity ratio has increased to 0.41 times, the highest in recent periods, though still moderate by industry standards. Institutional investor participation has waned, with a 3.44% reduction in stake over the previous quarter, leaving institutional holdings at just 2.47%. This decline in institutional interest often signals concerns about the company’s fundamentals.
Moreover, the stock has underperformed the benchmark indices consistently. Over the last year, Tarsons Products delivered a negative return of -34.92%, compared to a 5.52% gain in the Sensex. Over three years, the stock’s return is down by -66.72%, while the Sensex gained 32.25%. This persistent underperformance highlights the company’s struggles to generate shareholder value relative to the broader market.
Quality Parameters and Market Capitalisation Grade
Tarsons Products holds a market capitalisation grade of 4, indicating a mid-sized company within its sector. The overall Mojo Score stands at 31.0, with the Mojo Grade upgraded to Sell from Strong Sell on 10 March 2026. Despite the upgrade, the company’s quality metrics remain weak, reflecting its ongoing financial and operational challenges.
The company’s low debt-to-equity ratio averaging 0.35 times is a positive aspect, suggesting limited leverage risk. However, the subdued returns on capital and equity, combined with declining profitability and institutional interest, weigh heavily on the quality assessment.
Stock Price and Market Performance Context
Tarsons Products’ current stock price of ₹195.85 is closer to its 52-week low of ₹176.05 than its high of ₹457.25, underscoring the significant correction it has undergone. The stock’s recent weekly return of 1.42% outperformed the Sensex’s decline of -2.53%, but monthly and year-to-date returns remain negative at -10.24% and -16.07%, respectively, both worse than the benchmark.
This mixed performance suggests some short-term resilience amid longer-term weakness, consistent with the technical indicators’ mildly bullish weekly signals but bearish monthly outlook.
Considering Tarsons Products Ltd? Wait! SwitchER has found potentially better options in Healthcare Services and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Healthcare Services + beyond scope
- - Top-rated alternatives ready
Outlook and Investor Considerations
While the upgrade to Sell from Strong Sell reflects some technical stabilisation and a more balanced valuation, the fundamental outlook for Tarsons Products remains challenging. The company’s weak financial trends, including declining profits and returns, coupled with persistent underperformance against benchmarks, suggest caution for investors.
Institutional investors’ reduced participation further signals concerns about the company’s growth prospects and operational execution. The stock’s valuation, now fair rather than attractive, indicates that the market has priced in much of the company’s risks, leaving limited upside potential without a significant turnaround in fundamentals.
Investors should weigh the mildly improved technical signals against the ongoing financial headwinds and consider alternative opportunities within the healthcare services sector and broader market.
Summary of Rating Changes
To summarise, the key parameters influencing the rating change are:
- Quality: Remains weak due to poor profitability and negative financial trends.
- Valuation: Downgraded from attractive to fair, reflecting high PE and subdued returns.
- Financial Trend: Negative, with declining profits and operating margins over recent quarters.
- Technicals: Improved from bearish to mildly bearish, with short-term bullish signals supporting the upgrade.
These factors collectively led to the Mojo Grade upgrade to Sell, signalling a cautious stance for investors.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
